This is a working overview of WADA prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Flare-ups of autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis may also occur during this period. Patients on tumor necrosis factor antagonists Patients with chronic inflammatory conditions (Crohn's disease, ulcerative colitis, sarcoidosis, etc.) are often treated with TNF antagonists, such as infliximab, adalimumab, and etanercept. Tumor necrosis factors are critical in macrophage activation and subsequent granuloma formation. Therefore, TNF antagonists impair the host immune response against infections such as tuberculosis. While the patient is taking TNF antagonists, these infections may remain latent and asymptomatic. However, when these medications are discontinued, there may be an associated pro-inflammatory response causing the infection to be uncovered.
== Clinical significance == 11-Deoxycortisol in mammals has limited glucocorticoid activity, but it is the direct precursor of the major mammalian glucocorticoid, cortisol. As a result, the level of 11-deoxycortisol is measured to diagnose impaired cortisol synthesis, to find out the enzyme deficiency that causes impairment along the pathway to cortisol, and to differentiate adrenal disorders. In 11β-hydroxylase deficiency, 11-deoxycortisol and 11-deoxycorticosterone levels increase, and excess of 11-deoxycorticosterone leads to mineralocorticoid-based hypertension (as opposed to 21-hydroxylase deficiency, in which patients have low blood pressure from a lack of mineralocorticoids). Low levels of cortisol can affect blood pressure by causing a decrease in sodium retention and volume expansion. This effect occurs because cortisol regulates the balance of water and electrolytes in the body. When cortisol levels are low, there is less sodium reabsorption by the kidneys, leading to increased excretion of sodium through urine. This ultimately reduces blood volume and lowers blood pressure. On the other hand, high levels of cortisol can also affect blood pressure by causing an increase in sodium retention and volume expansion. Cortisol-induced hypertension is accompanied by significant sodium retention, leading to an increase in extracellular fluid volume and exchangeable sodium. This expansion results in an increase in blood volume and subsequently increases blood pressure.
Common adverse effects (2.4–42%) included agitation or irritability, tachycardia, hallucinations or delusions, confusion, pupil dilation, hypertension, drowsiness or lethargy, elevated creatine phosphokinase (CPK), nausea and vomiting, and others. Selected serious adverse effects included fever or hyperthermia in 3.8%, single seizure in 2.4%, coma in 1.4%, elevated creatinine in 1.4%, multiple seizures in 1.2%, rhabdomyolysis in 1.1%, respiratory depression in 0.9%, cardiac conduction disorder in 0.5%, and status epilepticus in 0.4%. There is a case report of severe neurological sequelae following a single typical recreational dose of LSD involving seizure and cardiorespiratory arrest. In general, psychedelics like LSD may rarely cause seizures in some individuals. The median lethal dose (LD50) of LSD in animals varies and is 50 to 60 mg/kg in mice, 16.5 mg/kg in rats, and 0.3 mg/kg in rabbits all given by injection. A well-known 1962 instance of an elephant named Tusko given 297 mg (~0.1 mg/kg) LSD by intramuscular injection proved fatal. These findings suggest that elephants may be much more sensitive to LSD in overdose than humans and other species. However, this instance has been mired in criticism and controversy due to miscalculation of LSD dose and concomitant post-LSD administration of promazine and pentobarbital. The experiment was repeated in two elephants with similar doses of LSD in 1984 without incident. Massive doses of LSD are largely managed by symptomatic treatments, and agitation can be addressed with benzodiazepines.
=== Radioactive isotopes === The existence of isotopes was first suggested in 1913 by the radiochemist Frederick Soddy, based on studies of radioactive decay chains that indicated about 40 different species referred to as radioelements (i.e. radioactive elements) between uranium and lead, although the periodic table only allowed for 11 elements between lead and uranium inclusive. Several attempts to separate these new radioelements chemically had failed. For example, Soddy had shown in 1910 that mesothorium (later shown to be 228Ra), radium (226Ra, the longest-lived isotope), and thorium X (224Ra) are impossible to separate. Attempts to place the radioelements in the periodic table led Soddy and Kazimierz Fajans independently to propose their radioactive displacement law in 1913, to the effect that alpha decay produced an element two places to the left in the periodic table, whereas beta decay emission produced an element one place to the right. Soddy recognized that emission of an alpha particle followed by two beta particles led to the formation of an element chemically identical to the initial element but with a mass four units lighter and with different radioactive properties. Soddy proposed that several types of atoms (differing in radioactive properties) could occupy the same place in the table. For example, the alpha-decay of uranium-235 forms thorium-231, whereas the beta decay of actinium-230 forms thorium-230.
== History == Jasons Market Place started its business in Singapore in 1975. It was introduced in Taiwan in 2003. In 2007, it opened in Hong Kong's Jardine's Lookout under the name "Market Place by Jasons". In 2012, Jasons Food Hall began operations in the Bangsar Shopping Centre, an upmarket shopping mall in the township of Bangsar, Malaysia, as a replacement for a Cold Storage store. Jasons Market Place in Taiwan was sold to Carrefour in 2020 and rebranded as Mia C'bon from 2022.
Sources: en.wikipedia.org
=== Preparation === Wheatgrass juice is cold-pressed from 7–9-day-old shoots, harvested before jointing, when chlorophyll, antioxidant enzymes, vitamin C, and phenolics peak. The grass should be washed with potable water, cold-pressed not blended or heated, and consumed within 10–15 minutes to avoid oxidation and enzyme loss. Heat, boiling, spray-drying, and high-speed blending are consistently discouraged due to chlorophyll degradation. When fresh juice is impractical, frozen fresh juice or low-temperature (<40 °C) dehydrated powder is acceptable with partial nutrient retention. Studies stress hygienic cultivation, pesticide-free medium, microbial and heavy-metal testing for safety. Wheatgrass juice is often available at juice bars, and some people grow and juice their own in their homes. It is available fresh as produce, in tablets, frozen juice, and powder. Wheatgrass is also sold commercially as a spray, cream, gel, massage lotion, and liquid herbal supplement.
Materials and samples from the original experiments remained in 2017 under the care of Miller's former student, Jeffrey Bada, a professor at the UCSD, Scripps Institution of Oceanography who also conducts origin of life research. As of 2013, the apparatus used to conduct the experiment was on display at the Denver Museum of Nature and Science.
== Mechanism of action == T3 and T4 bind to nuclear receptors (thyroid hormone receptors). T3 and T4, although being lipophilic, are not able to passively diffuse through the phospholipid bilayers of target cells, instead relying on transmembrane iodothyronine transporters. The lipophilicity of T3 and T4 requires their binding to the protein carrier thyroid-binding protein (TBG) (thyroxine-binding globulins, thyroxine binding prealbumins, and albumins) for transport in the blood. The thyroid receptors bind to response elements in gene promoters, thus enabling them to activate or inhibit transcription. The sensitivity of a tissue to T3 is modulated through the thyroid receptors.
Niosomes are vesicles composed of non-ionic surfactants, incorporating cholesterol as an excipient. Niosomes are utilized for drug delivery to specific sites to achieve desired therapeutic effects. Structurally, niosomes are similar to liposomes as both consist of a lipid bilayer. However, niosomes are more stable than liposomes during formation processes and storage. Niosomes trap hydrophilic and lipophilic drugs, either in an aqueous compartment (for hydrophilic drugs) or in a vesicular membrane compartment composed of lipid material (for lipophilic drugs).
Sources: en.wikipedia.org
Transport Corporation of India Limited is an Indian logistics and supply chain management company headquartered in Gurugram, Haryana, India. It was founded in 1958 by Prabhu Dayal Agarwal at Kolkata, India.
Roquefort blue cheese comes from the village of Roquefort-sur-Soulzon, France. Its flavors come from the use of unpasteurized sheep's milk, inoculation with Penicillium roqueforti, and the particular conditions of the natural caves of Roquefort-sur-Soulzon in which they are ripened. Penicillium roqueforti is the cause of the blue veins in Roquefort cheese. Various yeasts are also present, namely Debaryomyces hansenii and its non-sporulating form Candida famata, and Kluyveromyces lactis and its non-sporulating form Candida sphaerica. As with other blue cheeses, Roquefort's flavor and odor come from a mixture of methyl ketones such as 2-heptanone, 2-pentanone, and 2-nonanone.
===== MeSH D08.811.277.040 – acid anhydride hydrolases (EC 3.6) ===== MeSH D08.811.277.040.025 – adenosinetriphosphatase MeSH D08.811.277.040.025.095 – ca(2+) mg(2+)-atpase MeSH D08.811.277.040.025.125 – ca(2+)-transporting atpase MeSH D08.811.277.040.025.150 – dynein atpase MeSH D08.811.277.040.025.237 – muts dna mismatch-binding protein MeSH D08.811.277.040.025.281 – muts homolog 2 protein MeSH D08.811.277.040.025.303 – n-ethylmaleimide-sensitive proteins MeSH D08.811.277.040.025.325 – proton-translocating atpases MeSH D08.811.277.040.025.325.249 – bacterial proton-translocating atpases MeSH D08.811.277.040.025.325.500 – chloroplast proton-translocating atpases MeSH D08.811.277.040.025.325.625 – h(+)-k(+)-exchanging atpase MeSH D08.811.277.040.025.325.750 – mitochondrial proton-translocating atpases MeSH D08.811.277.040.025.325.875 – vacuolar proton-translocating atpases MeSH D08.811.277.040.025.450 – kinesin MeSH D08.811.277.040.025.525 – myosins MeSH D08.811.277.040.025.525.500 – myosin type i MeSH D08.811.277.040.025.525.750 – myosin type ii MeSH D08.811.277.040.025.525.750.124 – cardiac myosins MeSH D08.811.277.040.025.525.750.124.249 – atrial myosins MeSH D08.811.277.040.025.525.750.124.500 – ventricular myosins MeSH D08.811.277.040.025.525.750.374 – nonmuscle myosin type iia MeSH D08.811.277.040.025.525.750.500 – nonmuscle myosin type iib MeSH D08.811.277.040.025.525.750.750 – skeletal muscle myosins MeSH D08.811.277.040.025.525.750.875 – smooth muscle myosins MeSH D08.811.277.040.025.525.812 – myosin type iii MeSH D08.811.277.040.025.525.843 – myosin type iv MeSH D08.811.277.040.025.525.875 – myosin type v MeSH D08.811.277.040.025.600 – na(+)-k(+)-exchanging atpase MeSH D08.811.277.040.050 – apyrase MeSH D08.811.277.040.330 – gtp phosphohydrolases MeSH D08.811.277.040.330.200 – dynamins MeSH D08.811.277.040.330.200.100 – dynamin i MeSH D08.811.277.040.330.200.200 – dynamin ii MeSH D08.811.277.040.330.200.300 – dynamin iii MeSH D08.811.277.040.330.300 – gtp-binding proteins MeSH D08.811.277.040.330.300.100 – gtp phosphohydrolase-linked elongation factors MeSH D08.811.277.040.330.300.100.200 – peptide elongation factor g MeSH D08.811.277.040.330.300.100.700 – peptide elongation factor tu MeSH D08.811.277.040.330.300.100.800 – peptide elongation factor 1 MeSH D08.811.277.040.330.300.100.850 – peptide elongation factor 2 MeSH D08.811.277.040.330.300.200 – heterotrimeric gtp-binding proteins MeSH D08.811.277.040.330.300.200.100 – gtp-binding protein alpha subunits MeSH D08.811.277.040.330.300.200.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D08.811.277.040.330.300.200.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D08.811.277.040.330.300.200.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D08.811.277.040.330.300.200.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D08.811.277.040.330.300.200.100.400 – gtp-binding protein alpha subunits, gs MeSH D08.811.277.040.330.300.200.800 – transducin MeSH D08.811.277.040.330.300.400 – monomeric gtp-binding proteins MeSH D08.811.277.040.330.300.400.100 – adp-ribosylation factors MeSH D08.811.277.040.330.300.400.100.100 – ADP-ribosylation factor 1 MeSH D08.811.277.040.330.300.400.400 – rab gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.025 – rab1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.050 – rab2 gtp-binding protein MeSH D08.811.277.040.330.300.400.400.100 – rab3 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.100.500 – rab3a gtp-binding protein MeSH D08.811.277.040.330.300.400.400.150 – rab4 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.200 – rab5 gtp-binding proteins MeSH D08.811.277.040.330.300.400.450 – ral gtp-binding proteins MeSH D08.811.277.040.330.300.400.462 – ran gtp-binding protein MeSH D08.811.277.040.330.300.400.475 – rap gtp-binding proteins MeSH D08.811.277.040.330.300.400.475.100 – rap1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.500 – ras proteins MeSH D08.811.277.040.330.300.400.500.300 – oncogene protein p21(ras) MeSH D08.811.277.040.330.300.400.500.600 – proto-oncogene proteins p21(ras) MeSH D08.811.277.040.330.300.400.700 – rho gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.050 – cdc42 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.060 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D08.811.277.040.330.300.400.700.100 – rac gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.100.500 – rac1 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.200 – rhoa gtp-binding protein MeSH D08.811.277.040.330.300.400.700.300 – rhob gtp-binding protein MeSH D08.811.277.040.465 – nucleoside-triphosphatase MeSH D08.811.277.040.600 – pyrophosphatases MeSH D08.811.277.040.600.399 – inorganic pyrophosphatase MeSH D08.811.277.040.600.800 – thiamine pyrophosphatase MeSH D08.811.277.040.850 – thiamin-triphosphatase
== Bibliography == Borgelt LM, O'Connell MB, Smith JA, Calis KA (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 513–. ISBN 978-1-58528-194-7. Greenberger NJ, Blumberg R, Burakoff R, eds. (23 April 2009). Current Diagnosis and Treatment in Gastroenterology, Hepatology, and Endoscopy. McGraw Hill Professional. pp. 282–. ISBN 978-0-07-149007-8. South-Paul JE, Matheny SC, Lewis EL (4 September 2007). Current Diagnosis & Treatment in Family Medicine (Second ed.). McGraw-Hill Companies. ISBN 978-0-07-146153-5. Potts JM, ed. (2008). Genitourinary Pain and Inflammation: Diagnosis and Management. Springer. pp. 121–. ISBN 978-1-58829-816-4. Zderic S, Kirk J (15 September 2008). Pediatric Urology for the Primary Care Provider. Thoroughfare, NJ: SLACK Incorporated. pp. 22–. ISBN 978-1-55642-785-5.
Sipagladenant (INNTooltip International Nonproprietary Name; developmental code name KW-6356) is a non-xanthine selective antagonist or inverse agonist of the adenosine A2A receptor that was previously under development by Kyowa Kirin as a monotherapy and adjunctive to levodopa therapy in Parkinsonism. It reached phase 2 clinical trials prior to the discontinuation of its development in 2022.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.